Tackling nonadherence in psychiatric disorders: Current opinion

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1069-1077

  Farooq, Saeed ^a,b   Naeem, Farooq ^c  

^a STAFFORDSHIRE UNIVERSITY   (United Kingdom)

^b LADY READING HOSPITAL   (Pakistan)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Anxiety; Clinical practice; Compliance; Depression; Drug treatment; Psychosis

Indexed keywords

NEUROLEPTIC AGENT;

BEHAVIOR THERAPY; CLINICAL PRACTICE; COGNITIVE THERAPY; COMMUNITY CARE; EVIDENCE BASED MEDICINE; FAMILY ATTITUDE; HEALTH CARE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MEDICATION COMPLIANCE; MENTAL DISEASE; MOTIVATIONAL INTERVIEWING; PATIENT ATTITUDE; PSYCHOEDUCATION; PSYCHOTHERAPY; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT REFUSAL;

EID: 84902304759     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S40777     Document Type: Review

References (54)

1. Haynes R, Yao X, Degani A, Kripalani S, Garg A, McDonald H. Interventions to enhance medication adherence. Cochrane Database Syst Rev. 2005:1-96.
2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
3. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892-909.
4. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280-1288.
5. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692-699.
6. Jónsdóttir H, Opjordsmoen S, Birkenaes AB, et al. Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level. J Clin Psychopharmacol. 2010;30:169-175.
7. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007;58:1187-1192.
8. Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67:1542-1550.
9. Lingam R, Scott J. Treatment nonadherence in affective disorders. Acta Psychiatr Scand. 2002;105:164-172.
10. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry. 1996;153:993-1000.
11. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000;343:1942-1950.
12. Farooq S, Nazar Z, Irfan M, et al. Schizophrenia treatment adherence in a resource-poor setting: randomised controlled trial of Supervised Treatment in Outpatients for Schizophrenia (STOPS). Br J Psychiatry. 2011;199:467-472.
13. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants influence of patient-physician communication. JAMA. 2002;288:1403-1409.
14. Boudreau DM, Capoccia KL, Sullivan SD, et al. Collaborative care model to improve outcomes in major depression. Ann Pharmacother. 2002;36:585-591.
15. Kane JM, Perlis RH, DiCarlo LA, Au-Yeung K, Duong J, Petrides G. First experience with a wireless system incorporating physiologic assessments and direct confirmation of digital tablet ingestions in ambulatory patients with schizophrenia or bipolar disorder. J Clin Psychiatry. 2013;74:e533-e540.
16. Herz MI, Lamberti S, Mintz J, et al. A program for relapse prevention in schizophrenia. A controlled study. Arch Gen Psychiatry. 2000;57: 277-283.
17. Miller WR, Conforti K, Rollnik S. Motivational Interviewing: Preparing People for Change. 2nd ed. New York, NY, USA: The Guilford Press; 2002.
18. Patterson TL, Mausbach BT, McKibbin C, Goldman S, Bucardo J, Jeste DV. Functional adaptation skills training (FAST): a randomized trial of a psychosocial intervention for middle-aged and older patients with chronic psychotic disorders. Schizophr Res. 2006;86:291-299.
19. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry. 2002;159:1653-1664.
20. Lincoln TM, Wilheim K, Nestoriuc Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res. 2007;96: 232-245.
21. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011;6:CD002831.
22. Kemp R, Hayward P, Applewhaite G, et al. Compliance therapy in psychotic patients: randomized controlled trial. BMJ. 1996;312: 345-349.
23. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy: 18-month follow-up. Br J Psychiatry. 1998;172:413-419.
24. Merinder LB, Viuff AG, Laugesen HD, Clemmensen K, Misfelt S, Espensen B. Patient and relative education in community psychiatry: a randomized controlled trial regarding its effectiveness. Soc Psychiatry Psychiatr Epidemiol. 1999;34:287-294.
25. Gray R, Leese M, Bindman J, et al. Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry. 2006;189:508-514.
26. O'Donnell C, Donohoe G, Sharkey L, et al. Compliance therapy: a randomized controlled trial in schizophrenia. BMJ. 2003;327:834.
27. Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm. 2003;60:657-665.
28. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011.
29. Scott J. Cognitive and behavioral approaches to medication adherence. Adv Psychiatr Treat. 1999;5:338-347.
30. Vita A, Barlati S, Sacchetti E. Non pharmacological strategies to enhance adherence and continuity of care in schizophrenia. In: Sacchetti E, Vita A, Siracusano A, Fleischhacker W, editors. Adherence to Antipsychotics in Schizophrenia. Milan, Italy: Springer-Verlag; 2014.
31. Vaughan K, McConaghy N, Wolf C, Myhr C, Black T. Community treatment orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission. Aust N Z J Psychiatry. 2000;34:801-808.
32. Smith LS, Dawson J, Burns T. Supervised community treatment just as legitimate as compulsory hospital care. Br J Psychiatry. 2008;193:96-100.
33. Rugkåsa J, Dawson J. Community treatment orders: current evidence and the implications. Br J Psychiatry. 2013;203:406-408.
34. Swartz MS, Swanson JW, Wagner HR, Burns BJ, Hiday VA, Borum R. Can involuntary outpatient commitment reduce hospital recidivism? Findings from a randomized trial with severely mentally ill individuals. Am J Psychiatry. 1999;156:1968-1975.
35. Burns T, Rugkåsa J, Molodynksi A, et al. Community treatment orders for patients with psychosis: a randomised controlled trial (OCTET). Lancet. 2013;381:1627-1633.
36. Dye S, Dannaram S, Loynes B, Dickenson B. Supervised community treatment: 2-year follow-up study in Suffolk. Psychiatrist. 2012;36: 298-302.
37. Pfeiffer PN, Ganoczy D, Valenstein M. Dosing frequency and adherence to antipsychotic medications. Psychiatr Serv. 2008;59:1207-1210.
38. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1-46.
39. National Institute for Health and Care Excellence. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). Leicester, UK: British Psychological Society and Royal College of Psychiatrists; 2009. Available from: http://www.nice.org.uk/nicemedia/pdf/CG82NICEGuideline.pdf. Accessed February 14, 2014.
40. Rosenheck RA, Krystal JH, Lew R; CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364:842-851.
41. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40:192-213.
42. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603-609.
43. Couture SM, Roberts DL, Penn DL, Cather C, Otto MW, Goff D. Do baseline characteristics predict the therapeutic alliance in the treatment of schizophrenia? J Nerv Ment Dis. 2006;194(1):10-14.
44. Digiuseppe R, Linscott J, Jilton R. Developing the therapeutic alliance in child-adolescent psychotherapy. Appl Prev Psychol. 1996;5: 85-100.
45. Junghan UM, Leese M, Priebe S, Slade M. Staff and patient perspectives on unmet need and therapeutic alliance in community mental health services. Br J Psychiatry. 2011;191:543-547.
46. Misdrahi D, Petit M, Blanc O, Bayle F, Llorca PM, Perrens C. The influence of therapeutic alliance and insight on medication adherence in schizophrenia. Nord J Psychiatry. 2011;66:49-54.
47. Pringle J, Melczak M, Aldridge A, Snyder M, Smith R. Medication adherence and its relationship to the therapeutic alliance: results from an innovative pilot study within a community pharmacy MTM practice. Innov Pharm. 2011;2:1-14.
48. Thompson L, McCabe R. The effect of clinician-patient alliance and communication on treatment adherence in mental health care: a systematic review. BMC Psychiatry. 2012;12:87.
49. McCabe R, Khanom H, Bailey P, et al. Shared decision-making in ongoing outpatient psychiatric treatment. Patient Educ Couns. 2013;91: 326-328.
50. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12:216-226.
51. Weiden P, Rao N. Teaching medication compliance to psychiatric residents: placing an orphan topic into a training curriculum. Acad Psychiatry. 2005;29:203-210.
52. Torem SM. Participatory pharmacotherapy: 10 strategies for enhancing adherence. Curr Psychiatry. 2013;12:21-25. Available from http://www.currentpsychiatry.com/topics/practice-trends/article/participatory-pharmacotherapy-10-strategies-for-enhancing-adherence.html. Accessed March 11, 2014.
53. Harmon G, Lefante J, Krousel-Wood M. Overcoming barriers: the role of providers in improving patient adherence to antihypertensive medications. Curr Opin Cardiol. 2006;21(4):310-315.
54. Farooq S. Public health and physician focused strategies to improve medication adherence in psychotic disorders. World Psychiatry. 2013;12:258-240.